New Biosimilar Approvals for Myeloid Growth Factors and Anemia
Challenges remain in the acceptance of biosimilar medications by physicians, payers, and patients in the U.S., similar to the challenges faced by generic drugs when they were first introduced to the market.
  • Anemia
  • Myeloid Growth Factors
  • Recorded Webcast
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation